PT  - JOURNAL ARTICLE
AU  - Bittar, Mohamad
AU  - Deodhar, Atul
TI  - Ample Room for Improvement
AID  - 10.3899/jrheum.2025-0731
DP  - 2025 Sep 01
TA  - The Journal of Rheumatology
PG  - jrheum.2025-0731
4099  - http://www.jrheum.org/content/early/2025/08/25/jrheum.2025-0731.short
4100  - http://www.jrheum.org/content/early/2025/08/25/jrheum.2025-0731.full
AB  - In keeping with other immune-mediated inflammatory rheumatic diseases, treatment choices for axial spondyloarthritis (axSpA) have expanded beyond nonsteroidal antiinflammatory drugs (NSAIDs) and physical therapy in the last 20 years. We now have 10 advanced therapies from 3 distinct modes of action (ie, tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], and Janus kinase inhibitors [JAKi]), and novel modalities are being investigated.